CAS: 588-22-7; 2-(3,4-Dichlorophenoxy)Acetic Acid

上下游产品

CAS号95-77-2 3,4-二氯苯酚 | CAS号39975-26-3 sodium 3,4-dich... | CAS号105-36-2 溴乙酸乙酯 | CAS号15422-28-3 Acetamide,N-[(3... | CAS号15422-26-1 Acetamide, N-(4... | CAS号15422-29-4 Acetamide,N-[(4... | CAS号122-59-8 苯氧乙酸 | CAS号64673-07-0 2-(3,4-dichloro...

📜3,4-二氯苯酚置于lithium Hydroxide Monohydrate,Potassium Carbonate体系中,用 四氢呋喃,水,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 5.03H,反应生成 3,4-二氯苯氧基乙酸
参考文献: Chemcical Compounds[fr] Composés Chimiques
标题: Chemcical Compounds[fr] Composés Chimiques
摘要:该发明涉及取代吡咯烷衍生物.具体而言,该发明涉及符合以下式iii的化合物:其中a,B,L1,L2,L3,R1,R2,R3,R4,R5,R6,R9,R10,R30,Y1,Y2,Z2,Z4,Z5和z6如本文所定义,并其盐.该发明的化合物是atf4途径的抑制剂,可用于治疗癌症,癌前综合征以及与激活的未折叠蛋白应答途径相关的疾病,如阿尔茨海默病,脊髓损伤,创伤性脑损伤,缺血性中风,中风,糖尿病,帕金森病,亨廷顿病,克雅氏病,相关朊蛋白病,进行性核上性麻痹,肌萎缩侧索硬化,心肌梗死,心血管疾病,炎症,纤维化,肝脏慢性和急性疾病,肺部慢性和急性疾病,肾脏慢性和急性疾病,慢性创伤性脑病(cte),神经退行性疾病,痴呆,认知障碍,动脉粥样硬化,眼部疾病,心律失常,器官移植以及器官移植用途.因此,该发明进一步涉及包含该发明化合物的药物组合物.该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制atf4途径和治疗相关疾病的方法.

专利信息

专利号:WO-2023086801-A1
优先权日:2021-11-09
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2'). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-11920040-B2
优先权日:2018-05-29
标 题 :Carborhodamine compounds and methods of preparation thereof
发明人：LUKHTANOV EUGENY A
权利人:ELITECHGROUP MDX LLC
摘要:The carborhodamine dyes disclosed herein are novel reagents suitable for automated incorporation of carborhodamine dyes into oligonucleotides that can be used in detection methods for nucleic acid targets. This disclosure provides an efficient and simple process for the preparation of carborhodamine compounds and introduces previously unknown reagents for the automated synthesis of oligonucleotide-carborhodamine conjugates.

专利号:WO-2024256370-A1
优先权日:2023-06-13
标 题 :Synthesis of glufosinate using an amidase-based process
发明人：ZIMMERMANN GUNTHER; POTT MORITZ STEFAN
权利人:BASF SE
摘要:The present invention relates to a method of preparing glufosinate, comprising the steps of hydrolysing an N-carbamoyl glufosinate amide with an Amidase enzyme to form an N- carbamoyl amino acid compound followed by cleaving off the carbamoyl moiety of said N- carbamoyl amino acid compound.

专利号:US-2025120400-A1
优先权日:2021-12-10
标题:Synthesis of glufosinate using a hydantoinase-based process
发明人：DITRICH KLAUS; BREUER MICHAEL; POTT MORITZ STEFAN; ZIMMERMANN GUNTHER; SEEMAYER STEFAN
权利人:BASF SE
摘要:The present invention relates to a method of manufacturing glufosinate, comprising the steps of hydrolysing a hydantoin with a Hydantoinase enzyme to form a N-carbamoyl amino acid compound followed by cleaving off the carbamoyl moiety of said N-carbamoyl amino acid compound.

专利号:WO-2023205074-A1
优先权日:2022-04-18
标 题:Processes and intermediates for synthesis of adagrasib
发明人：SCATTOLIN THOMAS; GAN YONGHONG; CHEN CHENG; CHEN CHENGSHENG
权利人:MIRATI THERAPEUTICS INC
摘要:The present invention relates to new synthetic routes of synthesizing adagrasib. The invention also provides intermediates used in the provided synthetic routes.

专利号:US-2025207163-A1
优先权日:2022-03-25
标 题:Methods and apparatus for synthesizing nucleic acids
发明人：HOPKINS PATRYCJA A; SHAHSAVARI SHAHIEN; BEGOYAN VAGARSHAK; NJUMA OLIVE J; DEBENHAM HOLLY S; EFCAVITCH J WILLIAM; ALBIZATI KIM F
权利人:MOLECULAR ASSEMBLIES INC
摘要:Methods for the synthesis of polynucleotides using polymerases nucleotide analogs with labile terminator groups that allow stepwise addition of nucleotides are described. These nucleotide analogs may have a modification on 3′, 2′, or 3′-2′-bridged hydroxyl groups or on nucleobase moieties and can be used in the synthesis of natural or modified polynucleotides suitable for use in biological systems. The labile terminator groups are removed under mild conditions or by enzymes. They are accepted as substrates by polymerases. The synthesis may be carried out on a surface.